Baker Bros. Advisors
Latest statistics and disclosures from Baker Bros. Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are INCY, BGNE, ACAD, MDGL, RYTM, and represent 71.34% of Baker Bros. Advisors's stock portfolio.
- Added to shares of these 10 stocks: MRTX (+$159M), MDGL (+$98M), RVMD (+$71M), CERE (+$68M), REPL (+$42M), KYMR (+$32M), SERA (+$23M), EWTX (+$23M), BCYC (+$17M), ABCL (+$12M).
- Started 5 new stock positions in PFE, Neurogene, TYRA, CLDX, CERE.
- Reduced shares in these 10 stocks: Seagen (-$9.5B), , BGNE (-$198M), SWTX (-$69M), ROIV (-$48M), Praxis Precision Medicines I (-$39M), CABA (-$36M), BCRX (-$16M), RYTM (-$14M), COGT (-$13M).
- Sold out of its positions in ALEC, ANAB, ARVN, RNA, BMRN, BLUE, COGT, Genetron Hldgs, GERN, HRTX. Instil Bio, ITOS, MORF, NTRA, Neoleukin Therapeutics, PACB, Point Biopharma Global, Seagen, SWTX, SMMT, VOR, AFMD.
- Baker Bros. Advisors was a net seller of stock by $-9.7B.
- Baker Bros. Advisors has $8.8B in assets under management (AUM), dropping by -49.35%.
- Central Index Key (CIK): 0001263508
Tip: Access up to 7 years of quarterly data
Positions held by Baker Bros. Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Baker Bros. Advisors
Baker Bros. Advisors holds 84 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Incyte Corporation (INCY) | 25.8 | $2.3B | 36M | 62.79 |
|
|
BeiGene Sponsored Adr (BGNE) | 21.7 | $1.9B | -9% | 11M | 180.36 |
|
ACADIA Pharmaceuticals (ACAD) | 15.3 | $1.3B | 43M | 31.31 |
|
|
Madrigal Pharmaceuticals (MDGL) | 5.2 | $456M | +27% | 2.0M | 231.38 |
|
Rhythm Pharmaceuticals (RYTM) | 3.3 | $294M | -4% | 6.4M | 45.97 |
|
Mirati Therapeutics (MRTX) | 2.8 | $242M | +192% | 4.1M | 58.75 |
|
Immunocore Holdings Ads (IMCR) | 2.0 | $172M | 2.5M | 68.32 |
|
|
Kymera Therapeutics (KYMR) | 1.7 | $153M | +26% | 6.0M | 25.46 |
|
Revolution Medicines (RVMD) | 1.7 | $148M | +91% | 5.1M | 28.68 |
|
Invitae Corporation Notes 1.5% 4/1/2028 (Principal) | 1.5 | $131M | 300M | 0.44 |
|
|
Abcellera Biologics (ABCL) | 1.5 | $131M | +10% | 23M | 5.71 |
|
Roivant Sciences SHS (ROIV) | 1.0 | $85M | -36% | 7.6M | 11.23 |
|
Replimune Group (REPL) | 0.9 | $81M | +108% | 9.5M | 8.43 |
|
Entrada Therapeutics (TRDA) | 0.8 | $73M | 4.9M | 15.09 |
|
|
Ultragenyx Pharmaceutical (RARE) | 0.8 | $70M | +7% | 1.5M | 47.82 |
|
Cerevel Therapeutics Hldng I (CERE) | 0.8 | $68M | NEW | 1.6M | 42.40 |
|
Immatics SHS (IMTX) | 0.7 | $62M | +3% | 5.8M | 10.53 |
|
BioCryst Pharmaceuticals (BCRX) | 0.7 | $61M | -20% | 10M | 5.99 |
|
argenx SE Sponsored Adr (ARGX) | 0.7 | $58M | 151k | 380.43 |
|
|
Denali Therapeutics (DNLI) | 0.6 | $56M | +13% | 2.6M | 21.46 |
|
Akero Therapeutics (AKRO) | 0.6 | $55M | 2.4M | 23.35 |
|
|
Kodiak Sciences (KOD) | 0.6 | $53M | 17M | 3.04 |
|
|
Kiniksa Pharmaceuticals Com Cl A (KNSA) | 0.6 | $49M | 2.8M | 17.54 |
|
|
Xenon Pharmaceuticals (XENE) | 0.5 | $46M | +32% | 994k | 46.06 |
|
Prelude Therapeutics (PRLD) | 0.5 | $43M | 10M | 4.27 |
|
|
Cerus Corporation (CERS) | 0.5 | $42M | +12% | 20M | 2.16 |
|
Nurix Therapeutics (NRIX) | 0.5 | $40M | 3.9M | 10.32 |
|
|
Aerovate Therapeutics (AVTE) | 0.4 | $38M | -14% | 1.7M | 22.63 |
|
Ideaya Biosciences (IDYA) | 0.4 | $38M | 1.1M | 35.58 |
|
|
Edgewise Therapeutics (EWTX) | 0.4 | $34M | +196% | 3.1M | 10.94 |
|
Sera Prognostics Class A Com (SERA) | 0.4 | $33M | +258% | 5.4M | 5.98 |
|
Bicycle Therapeutics Sponsored Ads (BCYC) | 0.4 | $32M | +112% | 1.8M | 18.08 |
|
Igm Biosciences (IGMS) | 0.3 | $31M | +16% | 3.7M | 8.31 |
|
Biomea Fusion (BMEA) | 0.3 | $31M | 2.1M | 14.52 |
|
|
Monte Rosa Therapeutics (GLUE) | 0.3 | $28M | 4.9M | 5.65 |
|
|
Verve Therapeutics (VERV) | 0.3 | $24M | +19% | 1.7M | 13.94 |
|
Krystal Biotech (KRYS) | 0.2 | $21M | 170k | 124.06 |
|
|
Gracell Biotechnologies Sponsored Ads (GRCL) | 0.2 | $21M | +108% | 2.1M | 10.04 |
|
Immunovant (IMVT) | 0.2 | $18M | 425k | 42.13 |
|
|
Tscan Therapeutics (TCRX) | 0.2 | $16M | 2.8M | 5.83 |
|
|
Day One Biopharmaceuticals I (DAWN) | 0.2 | $15M | 1.0M | 14.60 |
|
|
DBV Technologies Sponsored Adr (DBVT) | 0.2 | $14M | 15M | 0.95 |
|
|
Relay Therapeutics (RLAY) | 0.1 | $13M | 1.2M | 11.01 |
|
|
Silverback Therapeutics (SPRY) | 0.1 | $11M | 2.0M | 5.48 |
|
|
Stoke Therapeutics (STOK) | 0.1 | $11M | +36% | 2.0M | 5.26 |
|
2seventy Bio (TSVT) | 0.1 | $11M | 2.5M | 4.27 |
|
|
Insmed Incorporated Com Par $.01 (INSM) | 0.1 | $11M | 343k | 30.99 |
|
|
Celldex Therapeutics (CLDX) | 0.1 | $9.8M | NEW | 248k | 39.66 |
|
Prime Medicine (PRME) | 0.1 | $9.1M | 1.0M | 8.86 |
|
|
Neurogene | 0.1 | $8.8M | NEW | 454k | 19.38 |
|
Adaptimmune Therapeutics Sponsored Adr (ADAP) | 0.1 | $8.7M | 11M | 0.79 |
|
|
Sana Biotechnology (SANA) | 0.1 | $8.2M | 2.0M | 4.08 |
|
|
Sagimet Biosciences Com Ser A (SGMT) | 0.1 | $7.9M | +78% | 1.5M | 5.42 |
|
Celcuity (CELC) | 0.1 | $7.8M | 536k | 14.57 |
|
|
Athira Pharma (ATHA) | 0.1 | $7.7M | 3.2M | 2.43 |
|
|
Opthea Sponsored Ads (OPT) | 0.1 | $7.6M | -3% | 2.6M | 2.95 |
|
Tango Therapeutics (TNGX) | 0.1 | $7.4M | 750k | 9.90 |
|
|
Taysha Gene Therapies Com Shs (TSHA) | 0.1 | $7.1M | +59% | 4.0M | 1.77 |
|
Hookipa Pharma Inc equity (HOOK) | 0.1 | $6.6M | 8.1M | 0.81 |
|
|
Invitae Corporation Series A Notes 4.5% 3/15/2028 (Principal) | 0.1 | $6.3M | 9.3M | 0.68 |
|
|
Mirum Pharmaceuticals (MIRM) | 0.1 | $5.6M | 191k | 29.52 |
|
|
Xencor (XNCR) | 0.1 | $5.2M | +99% | 245k | 21.23 |
|
Leap Therapeutics (LPTX) | 0.1 | $4.9M | 1.2M | 4.14 |
|
|
Design Therapeutics (DSGN) | 0.0 | $4.0M | 1.5M | 2.65 |
|
|
Talis Biomedical Corporation (TLIS) | 0.0 | $3.8M | 508k | 7.45 |
|
|
IsoRay (CATX) | 0.0 | $3.1M | 7.6M | 0.40 |
|
|
Vaxcyte (PCVX) | 0.0 | $3.1M | 49k | 62.80 |
|
|
Praxis Precision Medicines I | 0.0 | $2.9M | -93% | 132k | 22.28 |
|
Century Therapeutics (IPSC) | 0.0 | $2.6M | -30% | 798k | 3.32 |
|
Mersana Therapeutics (MRSN) | 0.0 | $2.5M | 1.1M | 2.32 |
|
|
Compass Therapeutics (CMPX) | 0.0 | $2.4M | 1.6M | 1.56 |
|
|
Achilles Therapeutics Sponsored Ads (ACHL) | 0.0 | $1.9M | -17% | 2.1M | 0.89 |
|
Kala Pharmaceuticals (KALA) | 0.0 | $1.9M | 267k | 7.00 |
|
|
Aligos Therapeutics (ALGS) | 0.0 | $1.4M | 2.1M | 0.66 |
|
|
Invitae (NVTA) | 0.0 | $1.1M | 1.8M | 0.63 |
|
|
Pfizer (PFE) | 0.0 | $1.0M | NEW | 35k | 28.79 |
|
Pmv Pharmaceuticals (PMVP) | 0.0 | $998k | 322k | 3.10 |
|
|
Aadi Bioscience (AADI) | 0.0 | $509k | -74% | 252k | 2.02 |
|
Protara Therapeutics Com Stk (TARA) | 0.0 | $374k | 200k | 1.88 |
|
|
Cabaletta Bio (CABA) | 0.0 | $303k | -99% | 13k | 22.70 |
|
Foghorn Therapeutics (FHTX) | 0.0 | $290k | 45k | 6.45 |
|
|
Atreca Cl A Com (BCEL) | 0.0 | $287k | -38% | 2.2M | 0.13 |
|
Tyra Biosciences (TYRA) | 0.0 | $147k | NEW | 11k | 13.85 |
|
Surrozen W Exp 8/11/2026 (SRZNW) | 0.0 | $16k | 833k | 0.02 |
|
Past Filings by Baker Bros. Advisors
SEC 13F filings are viewable for Baker Bros. Advisors going back to 2010
- Baker Bros. Advisors 2023 Q4 filed Feb. 14, 2024
- Baker Bros. Advisors 2023 Q3 filed Nov. 14, 2023
- Baker Bros. Advisors 2023 Q2 filed Aug. 14, 2023
- Baker Bros. Advisors 2023 Q1 filed May 15, 2023
- Baker Bros. Advisors 2022 Q4 filed Feb. 14, 2023
- Baker Bros. Advisors 2022 Q3 filed Nov. 14, 2022
- Baker Bros. Advisors 2022 Q2 filed Aug. 15, 2022
- Baker Bros. Advisors 2022 Q1 filed May 16, 2022
- Baker Bros. Advisors 2021 Q4 filed Feb. 14, 2022
- Baker Bros. Advisors 2021 Q3 filed Nov. 15, 2021
- Baker Bros. Advisors 2021 Q2 filed Aug. 16, 2021
- Baker Bros. Advisors 2021 Q1 filed May 17, 2021
- Baker Bros. Advisors 2020 Q4 filed Feb. 16, 2021
- Baker Bros. Advisors 2020 Q3 filed Nov. 16, 2020
- Baker Bros. Advisors 2020 Q2 filed Aug. 14, 2020
- Baker Bros. Advisors 2020 Q1 filed May 15, 2020